Datasets:

sarus-tech

/

phee

like 2

Follow

Sarus Technologies 9

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"by\"]], \"start\": [[53]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[31]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"anaphylaxis\"]], \"start\": [[41]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"calcitonin\"]], \"start\": [[56]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"calcitonin\"]], \"start\": [[56]], \"entity_id\": [\"T7\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[131]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"transient structured visual hallucinations\"]], \"start\": [[21]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a patient with vascular age-related macular degeneration (AMD)\"]], \"start\": [[67]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"an intravitreal Avastin-injection\"]], \"start\": [[141]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"vascular age-related macular degeneration (AMD)\"]], \"start\": [[82]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"Avastin\"]], \"start\": [[157]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"intravitreal\", \"injection\"]], \"start\": [[144, 165]], \"entity_id\": [\"T10\"]}}, \"Severity\": {\"text\": [[\"transient\"]], \"start\": [[21]], \"entity_id\": [\"T8\"], \"value\": \"Low\"}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Bortezomib\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Bortezomib\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"paralytic ileus\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"pulmonary toxicity\"]], \"start\": [[26]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"gemcitabine\"]], \"start\": [[6]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"metastatic gallbladder adenocarcinoma\"]], \"start\": [[48]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"gemcitabine\"]], \"start\": [[6]], \"entity_id\": [\"T7\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[76]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"stroke\", \"arterial spasm\"]], \"start\": [[31, 61]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"ergotamine overdosage\"]], \"start\": [[86]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"ergotamine\"]], \"start\": [[86]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[38]], \"entity_id\": [\"T9\"], \"value\": true}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[25]], \"entity_id\": [\"T10\"], \"value\": \"High\"}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[56]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"visual loss\"]], \"start\": [[37]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ethambutol\"]], \"start\": [[67]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"ethambutol\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"tuberculosis infection\"]], \"start\": [[94]], \"entity_id\": [\"T5\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"using\"]], \"start\": [[66]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"warfarin and vismodegib\"]], \"start\": [[72]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"warfarin\"], [\"vismodegib\"]], \"start\": [[72], [85]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[81]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"warfarin\"], [\"vismodegib\"]], \"start\": [[72], [85]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"Elevated International Normalized Ratio\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[43]], \"entity_id\": [\"T9\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[19]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"IDDM\"]], \"start\": [[14]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"interferon therapy\"]], \"start\": [[26]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"interferon\"]], \"start\": [[26]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"chronic viral hepatitis\"]], \"start\": [[49]], \"entity_id\": [\"T8\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurs\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Pseudomembranous colitis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"certain population groups\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"trimethoprim-sulfamethoxazole\"]], \"start\": [[88]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"trimethoprim\"], [\"sulfamethoxazole\"]], \"start\": [[88], [101]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"-\"]], \"start\": [[100]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"sulfamethoxazole\"], [\"trimethoprim\"]], \"start\": [[101], [88]], \"entity_id\": [\"T9\", \"T8\"]}}]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Budesonide\"]], \"start\": [[9]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Budesonide\"]], \"start\": [[9]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"contact dermatitis\"]], \"start\": [[34]], \"entity_id\": [\"T3\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"when\"]], \"start\": [[61]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Hypertension\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"most patients\"]], \"start\": [[25]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"most\"]], \"start\": [[25]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"after transplantation\", \"immunosuppression is based on cyclosporine and prednisone\"]], \"start\": [[39, 66]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cyclosporine\"], [\"prednisone\"]], \"start\": [[96], [113]], \"entity_id\": [\"T9\", \"T10\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[93]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"potassium loss\", \"hypokalemia\"]], \"start\": [[22, 101]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"phosphate\"]], \"start\": [[83]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"phosphate\"]], \"start\": [[83]], \"entity_id\": [\"T8\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[107]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"three patients with hepatitis C\"]], \"start\": [[18]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[18]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"Graves' disease\"]], \"start\": [[205]], \"entity_id\": [\"T1\"]}}, \"Treatment\": {\"text\": [[\"IFN-alpha and ribavirin\"]], \"start\": [[59]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"hepatitis C\"]], \"start\": [[38]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"IFN-alpha\"], [\"ribavirin\"]], \"start\": [[59], [73]], \"entity_id\": [\"T13\", \"T14\"]}}, \"Effect\": {\"text\": [[\"two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves' disease\"]], \"start\": [[117]], \"entity_id\": [\"T9\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[15]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Hepatotoxicity\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"choline magnesium trisalicylate\"]], \"start\": [[31]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"choline magnesium trisalicylate\"]], \"start\": [[31]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"case\"]], \"start\": [[64]], \"entity_id\": [\"T9\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[55]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"The 3 cases\", \"women with epilepsy\"]], \"start\": [[13, 148]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[17]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"women\"]], \"start\": [[148]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"reproductive endocrine disorders\"]], \"start\": [[70]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"after the initiation of valproate therapy\"]], \"start\": [[103]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[127]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"epilepsy\"]], \"start\": [[159]], \"entity_id\": [\"T12\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[74]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"A 43-year-old white man\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"43-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Race\": {\"text\": [[\"white\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"shallow erosion of a psoriatic plaque\"]], \"start\": [[36]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"chronic administration of methotrexate\"]], \"start\": [[80]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[106]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"psoriatic plaque\"]], \"start\": [[57]], \"entity_id\": [\"T11\"]}, \"Duration\": {\"text\": [[\"chronic\"]], \"start\": [[80]], \"entity_id\": [\"T12\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"from\"]], \"start\": [[104]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"visual field loss\"]], \"start\": [[86]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"hydroxychloroquine\"]], \"start\": [[109]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"hydroxychloroquine\"]], \"start\": [[109]], \"entity_id\": [\"T8\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Leflunomide\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[65]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"Leflunomide\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"toxic epidermal necrolysis\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with rheumatoid arthritis\"]], \"start\": [[50]], \"entity_id\": [\"T6\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[49]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"chromic phosphate administration\"]], \"start\": [[65]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"chromic phosphate\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Delayed bowel injury\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"was\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"amantadine\"]], \"start\": [[11]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"amantadine\"]], \"start\": [[11]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"cornea cleared\"]], \"start\": [[59]], \"entity_id\": [\"T4\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Potential_therapeutic_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treating\"]], \"start\": [[77]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"risperidone\"]], \"start\": [[28]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"psychosis\"]], \"start\": [[86]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"risperidone\"]], \"start\": [[28]], \"entity_id\": [\"T17\"]}}, \"Subject\": {\"text\": [[\"parkinsonian patients\"]], \"start\": [[99]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"parkinsonian\"]], \"start\": [[99]], \"entity_id\": [\"T15\"]}}, \"Negated\": {\"text\": [[\"not\"]], \"start\": [[43]], \"entity_id\": [\"T13\"], \"value\": true}}" }, { "event_id": "E2", "event_type": "Potential_therapeutic_event", "event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treating\"]], \"start\": [[77]], \"entity_id\": [\"T14\"]}, \"Subject\": {\"text\": [[\"parkinsonian patients\"]], \"start\": [[99]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"parkinsonian\"]], \"start\": [[99]], \"entity_id\": [\"T15\"]}}, \"Treatment\": {\"text\": [[\"clozapine\"]], \"start\": [[64]], \"entity_id\": [\"T20\"], \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[64]], \"entity_id\": [\"T16\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[31]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Spontaneous splenic infarction\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"sumatriptan\"]], \"start\": [[47]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"sumatriptan\"]], \"start\": [[47]], \"entity_id\": [\"T6\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[67]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Anaphylactoid reactions\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cisplatin\"]], \"start\": [[72]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[72]], \"entity_id\": [\"T6\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[95]], \"entity_id\": [\"T19\"]}, \"Effect\": {\"text\": [[\"widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer\"]], \"start\": [[105]], \"entity_id\": [\"T15\"]}, \"Subject\": {\"text\": [[\"a man\"]], \"start\": [[29]], \"entity_id\": [\"T16\"], \"Gender\": {\"text\": [[\"man\"]], \"start\": [[31]], \"entity_id\": [\"T21\"]}}, \"Treatment\": {\"text\": [[\"zonisamide for epilepsy\"]], \"start\": [[54]], \"entity_id\": [\"T17\"], \"Disorder\": {\"text\": [[\"epilepsy\"]], \"start\": [[69]], \"entity_id\": [\"T18\"]}, \"Drug\": {\"text\": [[\"zonisamide\"]], \"start\": [[54]], \"entity_id\": [\"T22\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[13]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"toxicity\"]], \"start\": [[4]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"cadmium, zinc, and cadmium/zinc mixtures at concentrations ranging from 10000 to 10 microg/l\"]], \"start\": [[16]], \"entity_id\": [\"T7\"], \"Dosage\": {\"text\": [[\"from 10000 to 10 microg/l\"]], \"start\": [[83]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"cadmium\"], [\"zinc\"], [\"cadmium\"], [\"zinc\"]], \"start\": [[16], [25], [35], [43]], \"entity_id\": [\"T10\", \"T11\", \"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"mixtures\"]], \"start\": [[48]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"cadmium\"], [\"zinc\"]], \"start\": [[35], [43]], \"entity_id\": [\"T13\", \"T14\"]}}]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[132]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"venlafaxine\"]], \"start\": [[115]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"venlafaxine\"]], \"start\": [[115]], \"entity_id\": [\"T12\"]}, \"Duration\": {\"text\": [[\"within the first week\"]], \"start\": [[169]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"acute myocardial ischaemia within the first week of treatment\"]], \"start\": [[142]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"an elderly woman with a pre-existing history of ischaemic heart disease\"]], \"start\": [[21]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[24]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[32]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"ischaemic heart disease\"]], \"start\": [[69]], \"entity_id\": [\"T10\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurring\"]], \"start\": [[57]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Vogt-Koyanagi-Harada disease\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"4 months after the start of interferon alpha\"]], \"start\": [[67]], \"entity_id\": [\"T6\"], \"Time_elapsed\": {\"text\": [[\"4 months\"]], \"start\": [[67]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"interferon alpha\"]], \"start\": [[95]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[18]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"probably\"]], \"start\": [[123]], \"entity_id\": [\"T8\"], \"value\": true}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"headache\"]], \"start\": [[21]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Capecitabine\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Capecitabine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[19]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Serotonin syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"concomitant treatment with linezolid and meperidine\"]], \"start\": [[25]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"linezolid\"], [\"meperidine\"]], \"start\": [[52], [66]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concomitant\"]], \"start\": [[25]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"linezolid\"], [\"meperidine\"]], \"start\": [[52], [66]], \"entity_id\": [\"T9\", \"T10\"]}}]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[42]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"valproate\"]], \"start\": [[32]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[32]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"hepatotoxic effects\"]], \"start\": [[50]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"a child\"]], \"start\": [[13]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[15]], \"entity_id\": [\"T9\"]}}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[26]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[30]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"isoniazid\"]], \"start\": [[6]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"isoniazid\"]], \"start\": [[6]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Acute\", \"neurotoxicity\"]], \"start\": [[0, 16]], \"entity_id\": [\"T4\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"inhibition\"]], \"start\": [[9]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient with systemic sclerosis\"]], \"start\": [[40]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"vitro inhibition of hematopoiesis\"]], \"start\": [[3]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"D-penicillamine\"]], \"start\": [[87]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"systemic sclerosis\"]], \"start\": [[55]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"D-penicillamine\"]], \"start\": [[87]], \"entity_id\": [\"T9\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[45]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Rhabdomyolysis\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors when coadministered with agents that may inhibit their metabolism\"]], \"start\": [[55]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"hydroxymethylglutaryl coenzyme A\"], [\"agents that may inhibit their metabolism\"]], \"start\": [[55], [144]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"coadministered\"]], \"start\": [[124]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"hydroxymethylglutaryl coenzyme A\"], [\"agents that may inhibit their metabolism\"]], \"start\": [[55], [144]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[36]], \"entity_id\": [\"T9\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"A 55-year-old woman\", \"a skin abscess\"]], \"start\": [[0, 135]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"55-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"acute urticaria and labial angioedema\"]], \"start\": [[44]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"ingesting 500 mg of cloxacillin\"]], \"start\": [[99]], \"entity_id\": [\"T8\"], \"Time_elapsed\": {\"text\": [[\"60 minutes\"]], \"start\": [[82]], \"entity_id\": [\"T12\"]}, \"Route\": {\"text\": [[\"ingesting\"]], \"start\": [[99]], \"entity_id\": [\"T13\"]}, \"Dosage\": {\"text\": [[\"500 mg\"]], \"start\": [[109]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"cloxacillin\"]], \"start\": [[119]], \"entity_id\": [\"T15\"]}, \"Disorder\": {\"text\": [[\"skin abscess\"]], \"start\": [[137]], \"entity_id\": [\"T16\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"provoked\"]], \"start\": [[5]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Acne\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"gold\"]], \"start\": [[17]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"gold\"]], \"start\": [[17]], \"entity_id\": [\"T6\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induce\"]], \"start\": [[70]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Taxanes\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Taxanes\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"pulmonary injury\"]], \"start\": [[77]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[57]], \"entity_id\": [\"T9\"], \"value\": true}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[54]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intravitreal bevacizumab injection\"]], \"start\": [[64]], \"entity_id\": [\"T4\"], \"Route\": {\"text\": [[\"intravitreal\", \"injection\"]], \"start\": [[64, 89]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"bevacizumab\"]], \"start\": [[77]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"two cases\"]], \"start\": [[19]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"acute endophthalmitis\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[82]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"mild hypothermia\"]], \"start\": [[33]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a 54-year old female patient\"]], \"start\": [[53]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"54-year old\"]], \"start\": [[55]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"risperidone\"]], \"start\": [[92]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"risperidone\"]], \"start\": [[92]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"schizophrenia\"]], \"start\": [[108]], \"entity_id\": [\"T11\"]}}, \"Severity\": {\"text\": [[\"subtle\"]], \"start\": [[25]], \"entity_id\": [\"T9\"], \"value\": \"Medium\"}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[22]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Mycophenolate mofetil\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Mycophenolate mofetil\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"neutropenia in liver transplantation\"]], \"start\": [[30]], \"entity_id\": [\"T5\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[126]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"new brain lesions\"]], \"start\": [[141]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"six weeks and 11 months of penicillamine therapy\"]], \"start\": [[62]], \"entity_id\": [\"T4\"], \"Duration\": {\"text\": [[\"six weeks and 11 months\"]], \"start\": [[62]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"penicillamine\"]], \"start\": [[89]], \"entity_id\": [\"T8\"]}}}" }, { "event_id": "E2", "event_type": "Potential_therapeutic_event", "event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[261]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"six weeks and 11 months of penicillamine therapy\"]], \"start\": [[62]], \"entity_id\": [\"T4\"], \"Duration\": {\"text\": [[\"six weeks and 11 months\"]], \"start\": [[62]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"penicillamine\"]], \"start\": [[89]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"excellent hepatic decoppering\"]], \"start\": [[227]], \"entity_id\": [\"T10\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"found\"]], \"start\": [[70]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"childhood nephrotic syndrome\"]], \"start\": [[98]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"childhood\"]], \"start\": [[98]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"nephrotic syndrome\"]], \"start\": [[108]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"chlorambucil\"]], \"start\": [[29]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"chlorambucil\"]], \"start\": [[29]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"central nervous toxicity\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[93]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"TEN\"]], \"start\": [[108]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Administration of lamotrigine\", \"with valproic acid\"]], \"start\": [[0, 57]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"valproic acid\"], [\"lamotrigine\"]], \"start\": [[62], [18]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[57]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"valproic acid\"], [\"lamotrigine\"]], \"start\": [[62], [18]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[77]], \"entity_id\": [\"T4\"], \"value\": true}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Docetaxel\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Docetaxel\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Meibomian duct inflammation and blockage\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with no history of eyelid masses in the past\"]], \"start\": [[103]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"likely\"]], \"start\": [[66]], \"entity_id\": [\"T9\"], \"value\": true}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[128]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"an exacerbation of Crohn's disease\"]], \"start\": [[93]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"a TNF-alpha inhibitor\"]], \"start\": [[131]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"TNF-alpha inhibitor\"]], \"start\": [[133]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"recipient\"]], \"start\": [[153]], \"entity_id\": [\"T8\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Rhabdomyolysis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intravenous vasopressin\"]], \"start\": [[42]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"vasopressin\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"Administration\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"intravenous nitroglycerin\"]], \"start\": [[18]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"idiopathic pulmonary hypertension\"]], \"start\": [[62]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[18]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"nitroglycerin\"]], \"start\": [[30]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"a patient with idiopathic pulmonary hypertension\"]], \"start\": [[47]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance\"]], \"start\": [[111]], \"entity_id\": [\"T10\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[33]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"increased libido\"]], \"start\": [[4]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[39]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"interfere\"]], \"start\": [[151]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"tacrolimus\"], [\"Coadministration of antidepressant agents such as nefazodone, or any other drug that inhibits the CYP3A4 isoenzyme subfamily\"]], \"start\": [[166], [0]], \"entity_id\": [\"T7\", \"T4\"], \"Drug\": {\"text\": [[\"tacrolimus\"], [\"nefazodone\"]], \"start\": [[166], [50]], \"entity_id\": [\"T11\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E3\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"Coadministration\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"nefazodone\"], [\"tacrolimus\"]], \"start\": [[50], [166]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"tacrolimus metabolism\"]], \"start\": [[166]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"should be anticipated\"]], \"start\": [[126]], \"entity_id\": [\"T9\"], \"value\": true}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[124]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"anaphylactoid reactions\"]], \"start\": [[100]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"a high dose combined with a short infusion time\", \"administration of intraperitoneal cisplatin\"]], \"start\": [[30, 133]], \"entity_id\": [\"T5\"], \"Dosage\": {\"text\": [[\"high dose\"]], \"start\": [[32]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[167]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"intraperitoneal\"]], \"start\": [[151]], \"entity_id\": [\"T9\"]}}, \"Speculated\": {\"text\": [[\"risk\"]], \"start\": [[92]], \"entity_id\": [\"T7\"], \"value\": true}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Human insulin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Human insulin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"lipoatrophy\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"from\"]], \"start\": [[22]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"phenobarbital\"]], \"start\": [[27]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"phenobarbital\"]], \"start\": [[27]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"chronic bilateral subdural hematomas\", \"sepsis\"]], \"start\": [[102, 143]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"Severe hepatotoxicity\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis.\"]], \"start\": [[53]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"infant\"]], \"start\": [[56]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"boy\"]], \"start\": [[63]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[73]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"clindamycin and trimethoprim-sulfamethoxazole\"]], \"start\": [[97]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"clindamycin\"], [\"trimethoprim\"], [\"sulfamethoxazole\"]], \"start\": [[97], [113], [126]], \"entity_id\": [\"T13\", \"T14\", \"T15\"]}, \"Combination\": [{\"event_id\": \"E3\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[109]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"clindamycin\"], [\"sulfamethoxazole\"], [\"trimethoprim\"]], \"start\": [[97], [126], [113]], \"entity_id\": [\"T13\", \"T15\", \"T14\"]}}]}, \"Effect\": {\"text\": [[\"Cholestatic liver disease with ductopenia (vanishing bile duct syndrome)\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"leading\"]], \"start\": [[147]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"itraconazole\", \"vincristine\"]], \"start\": [[65, 135]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"itraconazole\"], [\"vincristine\"]], \"start\": [[65], [135]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[105]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"itraconazole\"], [\"vincristine\"]], \"start\": [[65], [135]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"severe and even potentially fatal toxicities\"]], \"start\": [[158]], \"entity_id\": [\"T8\"]}, \"Severity\": {\"text\": [[\"severe and even potentially fatal\"]], \"start\": [[158]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurrence\"]], \"start\": [[66]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"tacrolimus nephrotoxicity\"]], \"start\": [[80]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"tacrolimus\"]], \"start\": [[80]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"tacrolimus\"]], \"start\": [[80]], \"entity_id\": [\"T7\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[60]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"D-Pen\"]], \"start\": [[70]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"D-Pen\"]], \"start\": [[70]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"bicytopenia\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[48]], \"entity_id\": [\"T5\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurring\"]], \"start\": [[74]], \"entity_id\": [\"T12\"]}, \"Effect\": {\"text\": [[\"lethal anuria\"]], \"start\": [[30]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"ifosfamide\", \"having received previous cisplatin chemotherapy\"]], \"start\": [[62, 97]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"ifosfamide\"], [\"cisplatin\"]], \"start\": [[62], [122]], \"entity_id\": [\"T16\", \"T17\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"received\"]], \"start\": [[104]], \"entity_id\": [\"T1\"]}, \"Drug\": {\"text\": [[\"ifosfamide\"], [\"cisplatin\"]], \"start\": [[62], [122]], \"entity_id\": [\"T16\", \"T17\"]}}]}, \"Subject\": {\"text\": [[\"a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension\"]], \"start\": [[87]], \"entity_id\": [\"T13\"], \"Disorder\": {\"text\": [[\"poor kidney perfusion\"]], \"start\": [[154]], \"entity_id\": [\"T14\"]}}, \"Speculated\": {\"text\": [[\"suspect\"]], \"start\": [[12]], \"entity_id\": [\"T15\"], \"value\": true}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Potential_therapeutic_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"administered\"]], \"start\": [[85]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"thiazide diuretics\"]], \"start\": [[98]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"polyuria\", \"nephrogenic diabetes insipidus\"]], \"start\": [[137, 150]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"thiazide diuretics\"]], \"start\": [[98]], \"entity_id\": [\"T12\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[66]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"acute renal failure with hyperkalemia\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"renin inhibitor aliskiren\"]], \"start\": [[111]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"aliskiren\"]], \"start\": [[127]], \"entity_id\": [\"T8\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[52]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with hemiparesis\"]], \"start\": [[21]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"hemiparesis\"]], \"start\": [[36]], \"entity_id\": [\"T4\"]}}, \"Effect\": {\"text\": [[\"irreversible lithium-effectuated neurotoxicity (SILENT)\"]], \"start\": [[78]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"lithium for a manic episode\"]], \"start\": [[159]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[159]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"manic episode\"]], \"start\": [[173]], \"entity_id\": [\"T9\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[65]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"uveitis\"]], \"start\": [[57]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"rifabutin therapy\"]], \"start\": [[81]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"rifabutin\"]], \"start\": [[81]], \"entity_id\": [\"T6\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[17]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Propylthiouracil\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Propylthiouracil\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"cutaneous vasculitis\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"prolong\"]], \"start\": [[57]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"fluoroquinolone antimicrobials\"]], \"start\": [[26]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"fluoroquinolone\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"corrected QT interval but rarely cause torsade de pointes\"]], \"start\": [[69]], \"entity_id\": [\"T5\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[16]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Succinylcholine\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"Succinylcholine\"]], \"start\": [[0]], \"entity_id\": [\"T1\"]}}, \"Subject\": {\"text\": [[\"a patient with mucositis\"]], \"start\": [[40]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"mucositis\"]], \"start\": [[55]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"hyperkalemia\"]], \"start\": [[24]], \"entity_id\": [\"T12\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[73]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"the first case\"]], \"start\": [[26]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"MTX\"]], \"start\": [[69]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"MTX\"], [\"MTX\"]], \"start\": [[69], [121]], \"entity_id\": [\"T7\", \"T8\"]}}, \"Effect\": {\"text\": [[\"gastric LPD\"]], \"start\": [[84]], \"entity_id\": [\"T6\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[94]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a patient with acute myeloblastic leukemia (AML)\"]], \"start\": [[12]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"several courses of chemotherapy, including macrophage-colony-stimulating factor (M-CSF)\"]], \"start\": [[110]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"acute myeloblastic leukemia\"]], \"start\": [[27]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"macrophage-colony-stimulating factor\"]], \"start\": [[153]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[129]], \"entity_id\": [\"T1\"]}}, \"Effect\": {\"text\": [[\"nephrotic syndrome\"]], \"start\": [[75]], \"entity_id\": [\"T7\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[14]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Actinomycin D\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Actinomycin D\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hepatic veno-occlusive disease\"]], \"start\": [[25]], \"entity_id\": [\"T5\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[12]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"foscarnet\"]], \"start\": [[142]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"foscarnet\"]], \"start\": [[142]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"nephrogenic diabetes insipidus and renal tubular acidosis\"]], \"start\": [[27]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[4]], \"entity_id\": [\"T7\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurring\"]], \"start\": [[35]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"13-cis-retinoic acid\"]], \"start\": [[67]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"13-cis-retinoic acid\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"cystic acne\"]], \"start\": [[92]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"acne fulminans\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[95]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Verapamil\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Verapamil\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"paroxysmal supraventricular tachycardia\"]], \"start\": [[48]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"proarrhythmic effect\"]], \"start\": [[107]], \"entity_id\": [\"T5\"]}, \"Negated\": {\"text\": [[\"little\"]], \"start\": [[100]], \"entity_id\": [\"T4\"], \"value\": true}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"zonisamide\"]], \"start\": [[30]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"zonisamide\"]], \"start\": [[30]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity syndrome\"]], \"start\": [[49]], \"entity_id\": [\"T7\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[43]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"hyperkalemia\"]], \"start\": [[26]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"low-dose heparin, within seven days of initiating heparin therapy\"]], \"start\": [[67]], \"entity_id\": [\"T6\"], \"Dosage\": {\"text\": [[\"low-dose\"]], \"start\": [[67]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[76]], \"entity_id\": [\"T11\"]}, \"Time_elapsed\": {\"text\": [[\"within seven days\"]], \"start\": [[85]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"patients with diabetes mellitus or chronic renal insufficiency\"]], \"start\": [[143]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"diabetes mellitus\"], [\"chronic renal insufficiency\"]], \"start\": [[157], [178]], \"entity_id\": [\"T8\", \"T9\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"anaemia and bone marrow aplasia\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Zidovudine\"]], \"start\": [[20]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Zidovudine\"]], \"start\": [[20]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"HIV\"]], \"start\": [[98]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"a patient infected with HIV\"]], \"start\": [[74]], \"entity_id\": [\"T8\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[103]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"adult Crohn's disease patient\"]], \"start\": [[26]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"adult\"]], \"start\": [[26]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"long-term AZA therapy\"]], \"start\": [[110]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"Crohn's disease\"]], \"start\": [[32]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"AZA\"]], \"start\": [[120]], \"entity_id\": [\"T10\"]}, \"Duration\": {\"text\": [[\"long-term\"]], \"start\": [[110]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"a parvovirus B19 infection and leukopenia\"]], \"start\": [[61]], \"entity_id\": [\"T6\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[29]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[16]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[16]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"papular eruption in psoriasis\", \"cutaneous vasculitis in collagen vascular disease\"]], \"start\": [[37, 138]], \"entity_id\": [\"T7\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[102]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"Two postmenopausal women\"]], \"start\": [[7]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[7]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"women\"]], \"start\": [[26]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"tamoxifen and progestational\"]], \"start\": [[45]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"tamoxifen\"]], \"start\": [[45]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"breast carcinoma\"]], \"start\": [[85]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"uterine enlargement and intermittent spotting\"]], \"start\": [[112]], \"entity_id\": [\"T9\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Tumor lysis syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"transcatheter arterial infusion of cisplatin and embolization\"]], \"start\": [[27]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"liver metastases of melanoma\"]], \"start\": [[101]], \"entity_id\": [\"T5\"]}, \"Route\": {\"text\": [[\"transcatheter arterial infusion\"]], \"start\": [[27]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[14]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Oxcarbazepine\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Oxcarbazepine\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Eosinophilia and Systemic Symptoms (DRESS)\"]], \"start\": [[41]], \"entity_id\": [\"T7\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Worsening of neurologic syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"patients with Wilson's disease\"]], \"start\": [[36]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"penicillamine therapy\"]], \"start\": [[80]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"penicillamine\"]], \"start\": [[80]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"Wilson's disease\"]], \"start\": [[50]], \"entity_id\": [\"T9\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[50]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"Patient A\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"right leg weakness\"]], \"start\": [[19]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"week 4 of CAP-XRT (1600 mg/m2)\"]], \"start\": [[57]], \"entity_id\": [\"T7\"], \"Duration\": {\"text\": [[\"week 4\"]], \"start\": [[57]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"CAP-XRT\"]], \"start\": [[67]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"1600 mg/m2\"]], \"start\": [[76]], \"entity_id\": [\"T11\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[63]], \"entity_id\": [\"T15\"]}, \"Subject\": {\"text\": [[\"A child\"]], \"start\": [[0]], \"entity_id\": [\"T12\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[2]], \"entity_id\": [\"T16\"]}}, \"Treatment\": {\"text\": [[\"phenobarbital\"]], \"start\": [[18]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"phenobarbital\"]], \"start\": [[18]], \"entity_id\": [\"T17\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity drug reaction\", \"which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis\"]], \"start\": [[32, 73]], \"entity_id\": [\"T14\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[65]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"aspirin\"]], \"start\": [[57]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"aspirin\"]], \"start\": [[57]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"asthma\"]], \"start\": [[73]], \"entity_id\": [\"T5\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Potential_therapeutic_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[119]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"tigecycline\"]], \"start\": [[134]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"tigecycline\"]], \"start\": [[134]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"pancreatitis, including abdominal pain\"]], \"start\": [[72]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"recommend\"]], \"start\": [[3]], \"entity_id\": [\"T6\"], \"value\": true}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[59]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"lichenoid eruption\"]], \"start\": [[40]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"the initiation of salsalate\"]], \"start\": [[65]], \"entity_id\": [\"T7\"], \"Duration\": {\"text\": [[\"initiation\"]], \"start\": [[69]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"salsalate\"]], \"start\": [[83]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"arthritic pain\"]], \"start\": [[107]], \"entity_id\": [\"T9\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"administration\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"lithium\"], [\"olanzapine\"]], \"start\": [[30], [43]], \"entity_id\": [\"T4\", \"T5\"], \"Drug\": {\"text\": [[\"lithium\"], [\"olanzapine\"]], \"start\": [[30], [43]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[38]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"lithium\"], [\"olanzapine\"]], \"start\": [[30], [43]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[64]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"NMS\"]], \"start\": [[85]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"at risk for\"]], \"start\": [[73]], \"entity_id\": [\"T8\"], \"value\": true}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[76]], \"entity_id\": [\"T15\"]}, \"Effect\": {\"text\": [[\"nausea, shortness of breath, azotemia, and hyperkalemia\"]], \"start\": [[91]], \"entity_id\": [\"T16\"]}, \"Treatment\": {\"text\": [[\"intravenous immunoglobulin\"]], \"start\": [[184]], \"entity_id\": [\"T17\"], \"Drug\": {\"text\": [[\"immunoglobulin\"]], \"start\": [[196]], \"entity_id\": [\"T21\"]}, \"Disorder\": {\"text\": [[\"myasthenia gravis\"]], \"start\": [[54]], \"entity_id\": [\"T22\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[184]], \"entity_id\": [\"T23\"]}}, \"Subject\": {\"text\": [[\"an 87-year-old white woman with myasthenia gravis\"]], \"start\": [[22]], \"entity_id\": [\"T13\"], \"Age\": {\"text\": [[\"87-year-old\"]], \"start\": [[25]], \"entity_id\": [\"T18\"]}, \"Race\": {\"text\": [[\"white\"]], \"start\": [[37]], \"entity_id\": [\"T19\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[43]], \"entity_id\": [\"T20\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"discontinued\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"adverse effects\"]], \"start\": [[76]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Linezolid\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Linezolid\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[48]], \"entity_id\": [\"T8\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[61]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Symptomatic visual field constriction\"]], \"start\": [[9]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"vigabatrin\"]], \"start\": [[77]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"vigabatrin\"]], \"start\": [[77]], \"entity_id\": [\"T6\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E2", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"adverse events\"]], \"start\": [[23]], \"entity_id\": [\"T14\"]}, \"Subject\": {\"text\": [[\"two patients\"]], \"start\": [[109]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[109]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"interaction between quetiapine and atazanavir-ritonavir\"]], \"start\": [[50]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"quetiapine\"], [\"atazanavir-ritonavir\"]], \"start\": [[70], [85]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E1\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[50]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"quetiapine\"], [\"atazanavir-ritonavir\"]], \"start\": [[70], [85]], \"entity_id\": [\"T12\", \"T13\"]}}]}, \"Effect\": {\"text\": [[\"Clinically significant\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Severity\": {\"text\": [[\"significant\"]], \"start\": [[11]], \"entity_id\": [\"T11\"], \"value\": \"Medium\"}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[54]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"two cases\"]], \"start\": [[21]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[21]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"methylphenidate\"]], \"start\": [[65]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"methylphenidate\"]], \"start\": [[65]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"fixed drug eruption\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Potential_therapeutic_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"indicated\"]], \"start\": [[50]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Linezolid\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"serious gram-positive infections\"]], \"start\": [[64]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"Linezolid\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[131]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"oxcarbazepine\"]], \"start\": [[117]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"oxcarbazepine\"]], \"start\": [[117]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"angioedema\"]], \"start\": [[142]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"pediatric patients aged 16 years and younger\"]], \"start\": [[156]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"16 years and younger\"]], \"start\": [[180]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"pediatric\"]], \"start\": [[156]], \"entity_id\": [\"T1\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"abnormal\"]], \"start\": [[156]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"abnormal liver function\"]], \"start\": [[156]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"receiving high doses of cyproterone acetate\"]], \"start\": [[67]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"cyproterone acetate\"]], \"start\": [[91]], \"entity_id\": [\"T7\"]}, \"Dosage\": {\"text\": [[\"high doses\"]], \"start\": [[77]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[58]], \"entity_id\": [\"T5\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[61]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"six cases\"]], \"start\": [[3]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"six\"]], \"start\": [[3]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"CT scans did not return to their original state\"]], \"start\": [[13]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"ACTH\"]], \"start\": [[67]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"ACTH\"]], \"start\": [[67]], \"entity_id\": [\"T9\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[52]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"infliximab\"]], \"start\": [[41]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"infliximab\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"membranous nephropathy\"]], \"start\": [[60]], \"entity_id\": [\"T5\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[36]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Thrombotic thrombocytopenic purpura\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"penicillamine\"]], \"start\": [[43]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[68]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"penicillamine\"]], \"start\": [[43]], \"entity_id\": [\"T10\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Potential_therapeutic_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"control\"]], \"start\": [[145]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"desensitization to NPH insulin, as well as standard insulin desensitization\"]], \"start\": [[62]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"allergic symptoms in a patient allergic to both NPH and regular insulin\"]], \"start\": [[153]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"NPH insulin\"], [\"standard insulin\"]], \"start\": [[81], [105]], \"entity_id\": [\"T7\", \"T11\"]}, \"Route\": {\"text\": [[\"desensitization\"], [\"desensitization\"]], \"start\": [[62], [122]], \"entity_id\": [\"T5\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"as well as\"]], \"start\": [[94]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"NPH insulin\"], [\"standard insulin\"]], \"start\": [[81], [105]], \"entity_id\": [\"T7\", \"T11\"]}}]}, \"Subject\": {\"text\": [[\"a patient allergic to both NPH and regular insulin\"]], \"start\": [[174]], \"entity_id\": [\"T13\"]}, \"Speculated\": {\"text\": [[\"whether\"]], \"start\": [[54]], \"entity_id\": [\"T8\"], \"value\": true}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a 24-year-old black woman\"]], \"start\": [[39]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"24-year-old\"]], \"start\": [[41]], \"entity_id\": [\"T9\"]}, \"Race\": {\"text\": [[\"black\"]], \"start\": [[53]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[59]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"Fulminant hepatic failure\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"propylthiouracil and propranolol\"]], \"start\": [[91]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"propylthiouracil\"], [\"propranolol\"]], \"start\": [[91], [112]], \"entity_id\": [\"T12\", \"T13\"]}, \"Disorder\": {\"text\": [[\"hyperthyroidism\"]], \"start\": [[128]], \"entity_id\": [\"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[108]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"propranolol\"], [\"propylthiouracil\"]], \"start\": [[112], [91]], \"entity_id\": [\"T13\", \"T12\"]}}]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"observed\"]], \"start\": [[126]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"hepatitis B vaccination\"]], \"start\": [[23]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"hepatitis B vaccination\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"mental nerve neuropathy\"]], \"start\": [[91]], \"entity_id\": [\"T4\"]}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[22]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Acute coronary events\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cisplatin-based chemotherapy\"]], \"start\": [[32]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[48]], \"entity_id\": [\"T7\"]}}}" } ] } ]

[ { "events": [ { "event_id": "E1", "event_type": "Adverse_event", "event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"peripheral neuropathy\"]], \"start\": [[45]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"CAP\"]], \"start\": [[83]], \"entity_id\": [\"T10\"]}, \"Negated\": {\"text\": [[\"not\"]], \"start\": [[91]], \"entity_id\": [\"T11\"], \"value\": true}}" } ] } ]